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analyses and meta-analyses were excluded. HRQoL out-
comes, functional outcomes and the principal ADHD symp-
tom-based outcome were extracted from included studies. 
An effect size of 0.5 versus placebo was used as a thresh-
old for potential clinical relevance (unreported effect sizes 
were calculated when possible). Of 291 records screened, 
35 articles describing 34 studies were included. HRQoL/
functioning was usually self-rated in adults and proxy-rated 
in children/adolescents. Baseline data indicated substantial 
HRQoL deficits in children/adolescents. Placebo-adjusted 
effects of medication on ADHD symptoms, HRQoL and 
functioning, respectively, were statistically or nominally 
significant in 18/18, 10/12 and 7/9 studies in children/ado-
lescents and 14/16, 9/11 and 9/10 studies in adults. Effect 
sizes were ≥0.5 versus placebo for symptoms, HRQoL and 
functioning, respectively, in 14/16, 7/9 and 4/8 studies in 
children/adolescents; and 6/12, 1/6 and 1/8 studies in adults. 
Effect sizes were typically larger for stimulants than for 
non-stimulants, for symptoms than for HRQoL/functioning, 
and for children/adolescents than for adults. The efficacy of 
ADHD medication extends beyond symptom control and 
may help reduce the related but distinct functional impair-
ments and HRQoL deficits in patients with ADHD.
Keywords Attention-deficit/hyperactivity disorder · 
Quality of life · Functional impairment · Randomized 
clinical trials · Systematic review
Introduction
Attention-deficit/hyperactivity disorder (ADHD) affects 
approximately 6.8% of children, 2.8% of adolescents and 
2.5% of adults worldwide [75, 76, 83]. The disorder is 
defined as persistent and developmentally inappropriate 
Abstract Children, adolescents and adults with attention-
deficit/hyperactivity disorder (ADHD) experience functional 
impairment and poor health-related quality of life (HRQoL) 
in addition to symptoms of inattention/hyperactivity–impul-
sivity. To synthesize qualitatively the published evidence 
from randomized, double-blind, placebo-controlled trials of 
the effectiveness of pharmacotherapy on functional impair-
ment or HRQoL in patients with ADHD, a systematic Pub-
Med searching and screening strategy was designed to iden-
tify journal articles meeting pre-specified criteria. Post hoc 
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symptoms of inattention and/or hyperactivity–impulsivity 
that interfere with a patient’s social, academic and/or occu-
pational functioning [8, 9]. The nature of functional impair-
ment varies from patient to patient and with age and may 
encompass diverse outcomes such as underperformance at 
school or at work, unemployment or low income, substance 
abuse, smoking, teenage pregnancy, arrest, divorce or 
acquiring sexually transmitted disease [61]. Health-related 
quality of life (HRQoL) is generally acknowledged to rep-
resent the impact of ill-health on an individual’s ‘percep-
tion of their position in life, in the context of culture and 
value systems in which they live, and in relation to their 
goals, expectations, standards and concerns’ [2, 104]. It 
has become clear that ADHD has a negative impact on 
patients’ HRQoL and that this may be further exacerbated 
by, or may increase the risk of, other psychiatric conditions 
such as anxiety and depression [31, 34, 54, 93]. Impaired 
day-to-day functioning in domains such as educational 
achievement and interpersonal relations is the reason that 
most often underlies a patient’s or parent’s decision to seek 
medical advice [72].
Pharmacotherapies for ADHD include the psychostimu-
lants methylphenidate (MPH) and amphetamines [includ-
ing the prodrug lisdexamfetamine (LDX)], and the non-
stimulants atomoxetine (ATX) and guanfacine. Guidelines 
recommend that drug therapy is used as part of a multi-
modal treatment plan, which should include psychoeduca-
tion or other non-pharmacological interventions such as 
parent training and cognitive behavioural therapy [13, 102]. 
Randomized controlled trials of pharmacotherapies in chil-
dren, adolescents and adults with ADHD have typically 
used a clinician-rated symptom scale as the primary effi-
cacy outcome measure, and meta-analyses of these studies 
have confirmed that ADHD medications are very effective 
in relieving patients’ symptoms [33, 77, 88, 89]. As recog-
nized in the recent European Medicines Agency guidance 
on inclusion of functional outcomes in clinical studies of 
ADHD medications [44], it is now widely acknowledged 
that treatment of ADHD should aim not only to relieve 
patients’ symptoms, but also to improve their functioning 
and HRQoL.
Assessing functional impairment or HRQoL in a ran-
domized controlled trial typically relies on completion 
of one or more of the many available ADHD-specific 
or generic questionnaires by patients themselves or by 
proxy raters (physicians, parents, teachers or family 
members) [30]. Use of these measures in clinical tri-
als of ADHD medications has grown rapidly in recent 
years [30]. Because ADHD is a behavioural disorder 
that affects multiple aspects of patients’ lives, the 18 
well-defined symptoms of ADHD interact and partially 
intersect with the constructs of functional impairment 
and HRQoL (Fig. 1). Although measures of functional 
impairment may share many similarities with measures 
of HRQoL, functional impairment is usually considered 
to be objective and ideally assessed by unbiased methods, 
whereas HRQoL is usually considered to be subjective 
and ideally assessed by the patients themselves. What 
precisely is being measured by a patient-rated functional 
impairment instrument or a proxy-rated HRQoL instru-
ment may therefore be open to debate and discussion [2]. 
Another important aspect of measuring functional impair-
ment and HRQoL is that the instruments should sample 
domains of impairment that are commonly affected by 
patients’ symptoms, but should not merely serve as sur-
rogate measures of symptoms. Moderate, but not strong, 
Fig. 1  Effects of ADHD on 
a patient’s life extend beyond 
symptoms. ADHD attention-
deficit/hyperactivity disorder
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correlations between measures of symptoms, functional 
impairment and HRQoL suggest that related, but distinct, 
constructs are being assessed [18, 19, 21, 32, 47, 81, 92, 
95].
These factors present challenges for the development 
and selection of instruments to measure HRQoL and 
functional impairment. Generic instruments have the 
advantage of capturing a broad picture of health status, 
but the potential disadvantage of poor sensitivity to the 
deficits characteristic of ADHD. Disorder-specific instru-
ments may offer improved sensitivity by specifying par-
ticular impairments, but may miss others. When any sin-
gle patient typically reports impairment in only a small 
proportion of the specified items within a domain, the 
instrument may suffer from poor sensitivity if the scoring 
system averages out this potentially severe and clinically 
relevant impairment across all the specified items within 
that domain. US Food and Drug Administration guidance 
on patient-reported outcome measures states that instru-
ments should be psychometrically validated and stand-
ardized to a reference population [46]. Standardization 
may present problems for ADHD-specific instruments if 
they are not designed for use in people who do not have 
ADHD. An advantage of generic instruments that are 
standardized to a reference population is that they ena-
ble direct comparison of the burden of disease in patients 
with ADHD with that of community norms and patients 
with other physical or mental health problems.
Results from clinical trials and observational stud-
ies using questionnaire-based instruments indicate that 
patients with ADHD experience severely compromised 
HRQoL [34]. In a 2010 systematic review of clinical tri-
als, open-label studies and post hoc analyses, evidence sup-
porting a positive short-term effect of medication on qual-
ity of life was limited mainly to studies of ATX in children 
and adolescents [29]. Recent evidence from observational 
and registry studies indicates that pharmacological treat-
ment of ADHD is associated with increased achievement 
and decreased absenteeism at school [16], a reduced risk 
of trauma-related emergency hospital visits [58], reduced 
risks of suicide and attempted suicide [28], and decreased 
rates of substance abuse [27] and criminality [56].
This systematic review focuses on the effect of pharma-
cological treatment of ADHD on functional impairment 
and HRQoL outcomes in randomized placebo-controlled 
studies. We aim to: survey the instruments used in these 
studies; assess the severity of baseline impairment relative 
to controls, when possible; collate the most robust evidence 
about the impact of medications on HRQoL and functional 
impairment outcomes; and assess the relationship of treat-
ment-related changes in these measures with changes in 
ADHD symptom scales.
Methods
A systematic literature searching and screening strat-
egy was designed to identify articles published in peer-
reviewed journals that reported findings of randomized 
placebo-controlled clinical trials of pharmacotherapy 
for ADHD using measures of functional impairment or 
HRQoL as outcomes. We extracted these outcomes for 
qualitative review and analysis, together with the prin-
cipal ADHD symptom-based outcomes from the same 
studies.
This systematic review was conducted in accord-
ance with the Preferred Reporting Items for System-
atic Reviews and Meta-Analyses (PRISMA) guidelines 
and was registered with the PROSPERO international 
prospective register of systematic reviews (identifier: 
CRD42015027595).
Search and selection
PubMed (http://www.ncbi.nlm.nih.gov/pubmed) was 
searched on 29 June 2016 using a search string (see Sup-
plementary Table 1) designed to identify journal articles 
in English that reported the results of randomized, pla-
cebo-controlled, human clinical trials of pharmacologi-
cal medications for ADHD that included assessments of 
functional impairment or HRQoL as study outcomes. 
Two individuals screened records independently and 
resolved all disagreements by discussion. In a first screen 
based on title and abstract, articles were excluded if they 
clearly failed to meet the inclusion criteria or met any of 
the exclusion criteria. In a second screen based on full 
text, articles were included only if they met all inclusion 
criteria and no exclusion criterion. References cited in all 
included articles were then screened in the same way.
Inclusion and exclusion criteria
Studies were included only if they enrolled participants 
with a primary diagnosis of ADHD. Participants could be 
children, adolescents and/or adults. ADHD diagnosis had 
to be based on the Diagnostic and Statistical Manual of 
Mental Disorders (DSM) III, IIIR, IV, IV-TR or 5 criteria 
[8–12]; the International Statistical Classification of Dis-
eases 10th Revision (ICD-10) criteria [103]; or on a diag-
nostic instrument that uses these criteria (e.g. ADHD Rat-
ing Scale IV [ADHD-RS-IV] [39], Schedule for Affective 
Disorders and Schizophrenia for School-Age Children-
Present and Lifetime Version (K-SADS-PL) [53], or Con-
ners’ Adult ADHD Diagnostic Interview for DSM-IV 
 Eur Child Adolesc Psychiatry
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[CAADID] [41]). Studies in patients with a primary diag-
nosis of another mental disorder and secondary comorbid 
ADHD were excluded.
Studies were included only if they assessed the effects 
of medication alone or in combination with non-pharma-
cological interventions. Medications did not need to have 
regulatory approval for the treatment of ADHD. Folic acid, 
omega-3 fatty acids and other dietary supplements were not 
considered to be medications.
Only randomized placebo-controlled studies with pro-
spectively defined comparisons between medication(s) and 
placebo were included. Studies could have parallel-group, 
crossover, treatment initiation or treatment withdrawal 
designs. Studies with an active control were included only 
if they also had a placebo control or placebo reference arm. 
Reviews and articles reporting post hoc analyses and meta-
analyses were excluded.
Only studies that assessed patients’ functional impair-
ment (or functioning) and/or HRQoL [or quality of life 
(QoL)] during randomized placebo-controlled treatment 
(not in a separate uncontrolled study period) were included. 
Instruments used for assessing these outcomes could be 
generic or disease-specific; investigator-rated, proxy-rated 
(e.g. by parents or teachers) or patient-rated; and did not 
need to be psychometrically validated. Assessments of any 
of the following were not eligible as measures of functional 
impairment: executive function, emotional dysregulation, 
emotional lability, mood, behaviour, (neuro)cognition, 
(neuro)cognitive function, (neuro)development, neuropsy-
chiatric function, memory, reaction time, alertness, psycho-
motor function, response inhibition, pre-pulse inhibition, 
lexical function, intelligence, sleep, creativity, anxiety and 
depression. ‘Global functioning’ measured using the Clini-
cal Global Impressions (CGI) scale was also not considered 
to be an eligible functional measure.
Data extraction and analysis
The following study details were extracted from each 
included article: duration of the randomized assessment 
period, age range of participants, active treatment(s) and 
doses, number of participants and randomization ratio. 
For each study, effect sizes and p values were extracted 
for functional impairment outcomes, HRQoL outcomes 
and the principal symptom-based outcome (e.g. ADHD-
RS-IV). When necessary, data for symptom-based out-
comes of a study were extracted from references cited 
in the included article. If relevant results from a single 
study were published in more than one article, the articles 
were treated as a single entity. When effect sizes were 
not reported, they were calculated from published data if 
possible (using ‘n’, mean change and standard deviation 
or standard error of the mean; or ‘n’ and F-statistic). An 
effect size threshold of 0.5 was used as an indicator of 
minimum clinically important differences in the qualita-
tive analysis [71].
The registered protocol for this systematic review 
(PROSPERO identifier: CRD42015027595) stated that 
meta-analysis would not be conducted unless sufficient 
studies of the same medication using the same functional/
(HR)QoL outcome measure over approximately the same 
treatment period were considered to have been identified 
in the searches.
Risk of bias
This review includes only study outcomes published 
in peer-reviewed journals. Functional impairment and 
HRQoL are usually secondary efficacy outcomes in 
ADHD studies and may be less likely to be reported than 
primary efficacy outcomes (e.g. ADHD symptoms). This 
could lead to bias if studies or study outcomes that indi-
cate favourable effects of medication are more likely to 
be published that those that do not. We did not formally 
assess the risk of bias in the studies or outcomes included 
in this review.
Post hoc analyses were excluded because they may be 
more likely than pre-specified analyses to report favour-
able effects of medication and are not typically controlled 
for multiple statistical comparisons. Pre-specified analy-
ses of secondary efficacy outcomes, however, may also 
not have been controlled for multiplicity of compari-
son and may be more likely to yield significant p values 
than primary analyses or secondary analyses that were 
included in a study-wide algorithm to control type I error. 
The p values quoted from some included studies may 
therefore represent nominal rather than strict statistical 
significance; both nominally significant and statistically 
significant p values are described as ‘significant’ in this 
review. To mitigate the associated risk of bias in favour 
of medication, we focus, when possible, on effect sizes 
of active medication versus placebo rather than p values 
to assess the efficacy of ADHD pharmacotherapy. This 
approach could lead to bias if studies with published or 
calculable effect sizes are more likely than those with-
out available effect sizes to report favourable effects of 
medication.
Results
Study selection
Of 288 articles identified by the search, 244 were 
excluded during screening of the title and abstract and 
a further ten were excluded during full-text screening. 
Eur Child Adolesc Psychiatry 
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Articles excluded at full-text screening reported stud-
ies that: lacked a comparison of medication with pla-
cebo [20, 60, 87], lacked an eligible HRQoL or func-
tional impairment outcome [23, 24, 26, 63, 74] or were 
post hoc analyses [62, 69]. The references cited in the 
remaining 34 included articles and in previous systematic 
reviews [29, 34, 88] were inspected, yielding three addi-
tional articles for screening based on title and abstract. 
Of these, two were excluded and one was screened based 
on full text and included [68], bringing the total number 
of included articles to 35. Two of these reported HRQoL 
data from the same study [84, 85], meaning that 34 stud-
ies were included for qualitative analysis (Fig. 2). Study 
data were extracted from all of the included articles and 
from eight additional articles that reported the symptom-
based outcomes for the included studies (Tables 1, 2). A 
meta-analysis was not conducted because the included 
articles were not considered to report enough comparable 
data from studies of the same medications in similar pop-
ulations and of similar duration for quantitative synthesis.
Patients, medications and outcomes assessed
Of the 34 included studies, 18 were conducted in chil-
dren aged 3–12 years and/or adolescents aged 13–18 years 
(Table 1), and 16 were conducted in adults aged 18 years 
or older (Table 2). None of the studies selected patients 
based on measures of HRQoL or functional impairment 
at baseline, but nearly all recruited patients with at least 
moderately severe ADHD symptoms (e.g. ADHD-RS-IV 
total score ≥28). Fourteen studies investigated stimulant 
medications (amphetamines, including LDX, and various 
formulations of MPH), and 21 studies investigated non-
stimulant medications (ATX, guanfacine extended release 
[GXR], metadoxine and reboxetine). Three studies inves-
tigated more than one medication. With the exception of 
metadoxine and reboxetine, all of the medications investi-
gated in the studies are approved for treatment of ADHD in 
one or more countries.
Twenty-nine studies were short-term double-blind 
studies (≤20 weeks); two were long-term (≥6 months) 
studies in children and adolescents (both double-blind, 
randomized withdrawal studies); and three were long-
term double-blind studies in adults (Tables 1, 2). Of 
the 18 studies in children and adolescents, 12 assessed 
HRQoL and 9 assessed functional impairment; of the 16 
adult studies, 12 assessed HRQoL and 11 assessed func-
tional impairment (Table 3).
HRQoL in children and adolescents was always 
assessed using generic instruments, but HRQoL in adults 
was mostly assessed using ADHD-specific instruments. 
Conversely, functional impairment was mostly assessed 
Fig. 2  PRISMA diagram. a35 
articles describing 34 studies. 
Symptom-based outcome data 
for studies reported in eight 
included articles were extracted 
from an additional eight articles 
cited in the included articles. 
PRISMA Preferred Reporting 
Items for Systematic Reviews 
and Meta-Analyses
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using ADHD-specific instruments in children and adoles-
cents, but generic instruments in adults. HRQoL in adults 
was self-rated in all studies, but proxy-rated (by parents) 
in all but three studies in children and adolescents (two 
in adolescents [42, 45] and one in children/adolescents 
[91]) (Table 3).
Baseline impairment
Some of the studies in children and adolescents used 
generic HRQoL instruments that have been standardized to 
community norms or for which reference population data 
are available. These can provide an indication of the burden 
of untreated ADHD when patients are assessed at baseline. 
The domains with the greatest deficits may reflect impair-
ments characteristic of the disorder and may also be con-
sidered as potential targets for treatment.
The Child Health and Illness Profile-Child Edition: 
Parent Report Form (CHIP-CE:PRF) is a generic, par-
ent-rated measure of children’s HRQoL in five domains 
(Achievement, Risk Avoidance, Resilience, Satisfaction 
and Comfort). Baseline CHIP-CE:PRF T-scores from five 
included studies (two of LDX and three of ATX) were 
strikingly consistent in indicating that children and ado-
lescents with ADHD have substantially impoverished 
HRQoL before treatment, especially in the Achievement 
and Risk Avoidance domains [14, 15, 37, 42, 91]. Impair-
ment was less marked in the domains of Resilience and 
Satisfaction, and scores in Comfort were close to the 
community norm [14, 15, 37, 42, 91]. These findings are 
also consistent with the results of two observational popu-
lation studies (not included in this review) that assessed 
the impact of ADHD on HRQoL using the CHIP-CE:PRF 
(Fig. 3) [32, 80].
The German, parent-rated Revidierter Fragebogen für 
Kinder und Jugendliche zur Erfassung der gesundheits‑
bezogenen Lebensqualität (KINDL-R; revised question-
naire to assess health-related quality of life in children and 
adolescents) also assesses children’s HRQoL overall and 
in six domains, namely Physical Well-Being, Emotional 
Well-Being, Self-Esteem, Friends, Family and School. 
In one included study [94], overall mean pre-treatment 
KINDL-R scores in children and adolescents with ADHD 
were substantially lower than the mean in the German ref-
erence population [22] [62.9 (95% confidence interval: 
61.0–64.8) vs 78.2 (77.8–78.7) on a scale of 0–100], with 
the largest deficits in the domains of Family and Friends, 
and no deficit in the Physical Well-Being domain. The par-
ent-rated Child Health Questionnaire-50-item Parent Form 
(CHQ-PF50) provides Psychosocial and Physical summary 
scores. In one included study, the mean baseline Psycho-
social T-score in children and adolescents with ADHD was 
almost two standard deviations below the normative mean 
(31.3–35.4 vs 50) [66].
Considered together, baseline parent-rated HRQoL data 
from the included child/adolescent studies indicate that 
parent-rated HRQoL of children with ADHD is approxi-
mately 1.5–2.0 standard deviations lower than that of con-
trol populations in domains reflecting achievement and 
risk-taking, as was also found in a previous systematic 
review [34]. HRQoL deficits may be less marked with self-
rated than with parent-rated instruments in children and 
adolescents. In one included study, mean T-scores on the 
self-rated Child Health and Illness Profile-Child Edition: 
Self-Report Form or Adolescent Edition (CHIP-CE:SRF/
AE) was not as far below the normative mean as those on 
the CHIP-CE:PRF [42]. This agrees with an observational 
study (not included in this review) in which self-rated 
CHIP-CE:SRF scores correlated only moderately with par-
ent-rated CHIP-CE:PRF T-scores [32]. In another included 
study [45], mean scores on the self-rated Youth Quality of 
Life Instrument-Research Version (YQOL-R) were not far 
below the mean for community norms [73] (79.2–79.5 vs 
82.2 on a 0–100 scale).
The other multi-domain instruments used in the stud-
ies included in this review do not have reference popula-
tion data. However, some domains consistently had worse 
pre-treatment scores than others. Weiss Functional Impair-
ment Rating Scale-Parent (WFIRS-P) baseline scores were 
generally worst in the Learning and School domain and in 
the Family domain in children and adolescents. In adults, 
ADHD Impact Module-Adult (AIM-A) scores were gen-
erally worst in the Performance and Daily Functioning 
domain, and Adult ADHD Quality of Life (AAQoL) scores 
were generally worst in the Productivity domain.
Effectiveness of pharmacological treatment in children 
and adolescents
ADHD symptoms in children and adolescents
All of the 18 studies in children and/or adolescents dem-
onstrated significant beneficial effects of medication on 
ADHD symptoms compared with placebo (Table 1). Effect 
sizes of active treatment versus placebo were reported for 
12 studies and were calculated using published data from 
four studies. Effect sizes of at least 0.5 (an approximate 
indicator of minimum clinically important difference) [71] 
for ADHD symptom outcomes in at least one active treat-
ment group were observed in all of these 16 studies except 
the long-term ATX withdrawal study [65] and the adjunc-
tive GXR study [100]. Effect sizes for symptom-based 
outcomes were generally lower for non-stimulants (range 
0.32–1.20) than for stimulants (range 0.80–1.80) (Table 4).
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HRQoL in children and adolescents
Of the 12 studies that assessed HRQoL, 10 reported signifi-
cant placebo-adjusted effects of medication in at least one 
domain or cross-domain summary statistic, all using patient 
proxy ratings (Table 1). Effect sizes of active treatment ver-
sus placebo were available for all but one of these studies 
[50] and were 0.5 or above in at least one domain in seven 
of the remaining nine [14, 15, 42, 66, 68, 91, 94].
Seven studies used multi-domain instruments (e.g. 
CHIP-CE:PRF, KINDL-R, CHQ-PF50) to assess changes 
in HRQoL with medication. Effect sizes varied across 
domains and were generally larger in domains relating to 
risk-taking and achievement than in domains relating to 
physical components of HRQoL in patients treated with 
ADHD medications (Table 4). In the most responsive 
domains, effect sizes observed for HRQoL were generally 
larger for stimulants (range 0.54–1.28) than for non-stimu-
lants (0.29–0.87).
The CHIP-CE:PRF was used in five studies: three short-
term studies of ATX [37, 42, 91], a short-term study of 
LDX with an osmotic-release oral system MPH (OROS-
MPH) reference arm [15], and a long-term, randomized 
withdrawal study of LDX (Table 4) [14]. In all of the short-
term studies, the largest effect sizes for active treatment 
versus placebo were in the Risk Avoidance and Achieve-
ment domains. The improvements in these domains with 
short-term LDX treatment [15] were maintained with con-
tinued treatment in the subsequent randomized withdrawal 
study [14]. Results in the Resilience and Satisfaction 
domains differed across studies, with significant effects and 
small or moderate effect sizes in the LDX studies but not 
in the ATX studies. In the Comfort domain, no significant 
effects of treatment were reported in any study [14, 15, 37, 
42, 91]. In the study of ATX using the KINDL-R, signifi-
cant beneficial effects of ATX were reported in all domains 
except School and Physical Well-Being, with a significant 
effect in favour of placebo in the latter [94]. This suggests 
Table 3  Instruments used to measure HRQoL/functional outcomes
a
 Parent version of CHQ assumed (not specified in article) [68]
b
 DAS (patient), PSI (patient), PSCS (patient), FAM-III (patient) and APQ-Patient (patient)
AAQoL Adult ADHD Quality of Life, ADHD attention-deficit/hyperactivity disorder, AIM-A ADHD Impact Module-Adult, APQ Alabama 
Parenting Questionnaire, APRS Academic Performance Rating Scale, BSFQ Before-School Functioning Questionnaire, CHIP-CE:PRF Child 
Health and Illness Profile-Child Edition: Parent Report Form, CHIP-CE:SRF/AE Child Health and Illness Profile-Child Edition: Self-Report 
Form/Adolescent Edition, CHQ-PF50 Child Health Questionnaire-50-item Parent Form, DAS Dyadic Adjustment Scale, DBS Driving Behavior 
Survey, EWPS Endicott Work Productivity Scale, FAM-III Family Assessment Measure III Dyadic Relationship Scales, GAF Global Assessment 
of Functioning, HRQoL health-related quality of life, JTJA Jag Tycker Jag Är [I think I am], KINDL-R Revidierter Fragebogen für Kinder und 
Jugendliche zur Erfassung der gesundheitsbezogenen Lebensqualität [Revised questionnaire to assess health-related quality of life in children 
and adolescents], Q-LES-Q Quality of Life Enjoyment and Satisfaction Questionnaire, PSCS Parenting Sense of Competence Scale, PSI Parent-
ing Stress Index, SCS-P/T Social Competence Scale-Parent/Teacher, SDS Sheehan Disability Scale, SSRS-P/T Social Skills Rating System-Par-
ent/Teacher, WFIRS-P Weiss Functional Impairment Rating Scale-Parent, YQOL-R Youth Quality of Life Instrument-Research Version
Generic (rater) ADHD-specific (rater)
Studies in children and adolescents
 HRQoL CHIP-CE:PRF (parent) – 5 studies
[14, 15, 37, 42, 91]
CHQ-PF50 (parent)a—5 studies
[17, 50, 65, 66, 68]
YQOL-R (patient)—1 study [45]
KINDL-R (parent)—1 study [94]
JTJA (patient)—1 study [91]
CHIP-CE:SRF/AE (patient)—1 study [42]
 Functional impairment SCS-P/T (parent/teacher); SSRS-P/T (parent/teacher)—1 study [1]
APRS (teacher)—1 study [17]
WFIRS-P (parent)—5 studies
[14, 15, 51, 86, 101]
BSFQ (patient/parent; investigator)—2 studies [99, 100]
Studies in adults
 HRQoL Q-LES-Q (patient)—1 study [82] AAQoL (patient)—8 studies
[3, 5–7, 40, 48, 55, 59]
 Functional impairment with HRQoL 
element
AIM-A (patient)—3 studies
[3, 25, 84, 85]
Functional impairment SDS (patient)—5 studies
[25, 52, 78, 82, 96]
GAF (investigator)—1 study [79]
DBS (patient or observer)—1 study [7]
EWPS (patient)—1 study [7]
Various family functioning measures (patient)b—1 study [97]
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that the KINDL-R Physical Well-Being domain may be 
more sensitive to side effects of medication than other 
instruments [94].
Three of the five studies that used the CHQ-PF50 
reported significant placebo-adjusted improvements in Psy-
chosocial summary score, with effect sizes of 0.29–0.87 
for ATX and 0.54 for OROS-MPH (the reference arm in 
one ATX study, in which the ATX effect size was 0.37) 
(Table 4) [65, 66, 68]. Effect sizes were not available for 
one [50]. In the remaining study, the improvement in Psy-
chosocial summary score with ATX treatment was not sig-
nificant, but a significantly greater proportion of patients 
receiving ATX were classified as CHQ-PF50 responders, 
compared with placebo (43.8 vs 22.2%; p < 0.04) [17]. The 
effect size of 0.32 and relatively small number of patients 
(N = 153) suggests that this study may have been statisti-
cally underpowered. Physical summary score was reported 
in only one of the studies to use the CHQ-PF50 [66], which 
showed negative and non-significant effect sizes of ATX 
versus placebo (Table 4).
Functional impairment in children and adolescents
Five of the nine studies that assessed functional impairment 
in children and adolescents used the parent-rated WFIRS-
P. Four of these five studies (three short-term studies and 
one randomized withdrawal study) reported significant pla-
cebo-adjusted effects of treatment on WFIRS-P total score 
(Table 4) [14, 15, 51, 86]. Scores in the Family domain and 
the Learning and School domain were most consistently 
improved relative to placebo in these studies. Effects were 
not consistent in other domains, although scores in the Life 
Skills and Child’s Self-Concept domains were the least 
responsive to treatment (Table 4). In the most responsive 
domains, WFIRS-P effect sizes were larger for stimulants 
(range 0.86–1.25) than for non-stimulants (0.32–0.58). 
Three studies reported significant effects of medications on 
single-domain functional impairment measures (Table 1) 
[1, 99, 100], with an effect size above 0.5 in a study of 
transdermal MPH (TD-MPH) using the Before-School 
Functioning Questionnaire (BSFQ) [99].
Fig. 3  Pre-treatment baseline CHIP-CE:PRF T-scores in children and 
adolescents with ADHD. T-scores have a mean of 50 and a standard 
deviation of 10. Circle diameter is proportional to T-score, with a 
diameter of zero corresponding to a T-score of 20. Rings indicate the 
mean in the reference population. aStudy SPD489-326 [15] (included 
in this review) involved mainly the same patients as the short-term 
LDX study SPD489-325 [14] (also included in this review), so only 
the former is shown. bPooled analysis of five ATX studies [43]: three 
randomized placebo-controlled trials (included in this review) [37, 
42, 91], and two open-label studies (not included in this review). cOb-
servational study (not included in this review), shown for compari-
son [80]. dObservational study with non-ADHD control groups (not 
included in this review), shown for comparison [32]. ADHD atten-
tion-deficit/hyperactivity disorder, ADORE Attention-Deficit/Hyper-
activity Disorder Observational Research in Europe, ATX atomox-
etine, CHIP-CE:PRF Child Health and Illness Profile-Child Edition: 
Parent Report Form, LDX lisdexamfetamine, T1DM type 1 diabetes 
mellitus
 Eur Child Adolesc Psychiatry
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Patient self‑rating and proxy ratings in children 
and adolescents
Results from several studies suggest that observed treat-
ment effects may be larger when questionnaires are com-
pleted by proxies than by patients, both for instruments 
described as HRQoL measures and those described as 
functional impairment measures. This mirrors the greater 
baseline HRQoL deficits observed with parent-rated than 
with self-rated HRQoL instruments.
The self-rated CHIP-CE:SRF/AE and parent-rated 
CHIP-CE:PRF were used together in one study of ATX 
[42]. The pattern of changes observed across the five 
domains was similar with the CHIP-CE:SRF/AE and the 
CHIP-CE:PRF, but effect sizes were smaller with the self-
rated than with the parent-rated instrument in all domains 
except Satisfaction (Table 4). An effect size above 0.5 for 
ATX versus placebo was seen only in the CHIP-CE:PRF 
Risk Avoidance domain in this study. In another of the 
ATX studies that used the CHIP-CE:PRF, the significant 
effects of ATX versus placebo in the Achievement domain 
and the Risk Avoidance domain (effect sizes, 0.53 and 
0.41, respectively; Table 4) were not reflected in a one-
dimensional self-rated Swedish HRQoL scale (effect size 
0.10). It is possible that this scale, the Jag Tycker Jag Är 
[I think I am] (JTJA), may not be sensitive to HRQoL 
deficits in patients with ADHD [91]. Similarly, self-rated 
YQOL-R scores did not significantly improve from base-
line to endpoint in either the LDX or placebo groups (and 
did not differ between groups) of a study in adolescents, 
despite an effect size for LDX 70 mg of 0.72 (p ≤ 0.0056) 
on ADHD symptoms in the same study [45].
Two studies used the BSFQ, an ADHD-specific instru-
ment with a proxy-rated section (completed by investiga-
tors or parents; Table 4) and a self-rated section (com-
pleted by patients in collaboration with their parents). In 
one study, significantly greater improvement with TD-
MPH than with placebo was observed using the investiga-
tor-rated BSFQ, with an effect size of 1.08 (p < 0.01), but 
not using the self-reported BSFQ [99]. Similarly, signifi-
cantly greater improvement with GXR than with placebo 
as an adjunct to stimulant medication was observed using 
the parent-rated BSFQ (effect size 0.38–0.39; p < 0.001), 
but not using the self-rated BSFQ [100].
Effectiveness of pharmacological treatment on HRQoL 
and functional impairment in adults
ADHD symptoms in adults
Of the 16 included studies conducted in adults, 14 dem-
onstrated significant beneficial effects of medication on 
ADHD symptoms compared with placebo (Table 2). 
Effect sizes were available for ADHD symptom outcomes 
in 12 of these 14 studies and were 0.5 or above in three 
of the five studies of stimulants and three of the seven 
studies of non-stimulants (Table 5). Effect sizes could 
not be calculated for two studies that reported significant 
effects of medications on ADHD symptoms [52, 85]. Two 
studies did not find significant effects of medication on 
ADHD symptoms: a parallel-group study of reboxetine 
(reboxetine, n = 23; placebo, n = 17) [79], and a paral-
lel-group study of dextroamphetamine in patients receiv-
ing cognitive behavioural therapy (dextroamphetamine, 
n = 23; placebo, n = 25) [96].
HRQoL in adults
Of the 11 studies that assessed HRQoL in adults, signifi-
cant improvement versus placebo in at least one measure or 
domain was reported in nine (Table 2). Of these nine, effect 
sizes were available for six and were 0.5 or above only 
in a 10-week study of LDX that used the AAQoL [3]. In 
the studies that used the AAQoL, placebo-adjusted effects 
varied across the four domains, with the largest effect 
sizes usually in the Life Productivity domain (0.21–0.91) 
(Table 5) [3, 5–7, 40, 48, 55]. The other HRQoL measures 
used in adults were the Quality of Life Enjoyment and Sat-
isfaction Questionnaire (Q-LES-Q) [82] and the Overall 
Quality of Life (QoL) section of the AIM-A. Significant 
effects of stimulants versus placebo were reported using the 
latter measure in two studies, with an effect size of 0.44 for 
LDX [3, 84, 85].
Functional impairment in adults
Of the 10 studies that assessed functional impairment in 
adults, significant improvements versus placebo in at least 
one measure were reported in nine (Table 2). Of these nine 
studies, effect sizes were available for eight and were 0.5 or 
above in at least one measure or domain in only one study 
(Table 5) [3]. This revealed significant effects of LDX in all 
six domains of the AIM-A, with effect sizes of 0.93 in the 
Performance and Daily Functioning domain and 0.57–0.79 
in four of the remaining five domains (p < 0.05) (Table 5) 
[3]. Effect sizes were not calculable for the other two stud-
ies that used the AIM-A, but significant placebo-adjusted 
effects of MAS-XR3 (triple-bead mixed amphetamine salts 
extended release) were reported in all domains in one study 
[85] and of OROS-MPH in three to four domains, depend-
ing on dose, in the other [25]. Five studies used the self-
rated Sheehan Disability Scale (SDS), a global measure 
of functional impairment across domains of Work/School, 
Social Life and Family Life. Significant effect sizes of 
long-acting MPH versus placebo were about 0.4 in three of 
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Table 4  Summary of treatment effect sizes in children and adolescents
Study and instrument Treatment Effect sizes of acve treatment versus placeboa
Studies with
HRQoL outcomes
Symptoms HRQoL
CHIP-CE:PRFc (parent-rated)
ADHD-RS-IV (or 
SNAP-IV ADHD)g
Achievement Risk Avoidance Resilience Sasfacon Comfort
Banaschewski et al. 2013 [15] LDX 1.80*** 1.28*** 1.08*** 0.42** 0.37* 0.00NS
OROS-MPH 1.26*** 0.91*** 0.95*** 0.40* 0.35* 0.18NS
Banaschewski et al. 2014 [14] LDX connuaon 1.49*** 0.70*** 0.83*** 0.28NS 0.64*** 0.35NS
Svanborg et al.
2009 [90, 91]b
ATX 1.20*** 0.53* 0.41* 0.03NS –0.12NS –0.17NS
Dell’Agnello et al. 2009 [37]b,h ATX 0.73*** 0.31NS across all domains; significant in Risk Avoidance* only
Escobar et al. 2009 [42] ATX 0.82*** [67] 0.29* 0.56*** 0.11NS 0.03NS 0.16NS
CHIP-CE:SRF/AEc (self-rated) ADHD-RS-IV Achievement Risk Avoidance Resilience Sasfacon Comfort
Escobar et al. 2009 [42] ATX 0.82*** [67] 0.09NS 0.39** 0.02NS 0.14NS 0.10NS
CHQ-PF50c,d (parent-rated) ADHD-RS-IV Psychosocial summary score Physical summary score
Brown et al. 2006 [17] ATX 0.62** 0.32NS NR
Michelson et al. 2001 [66]b ATXe 0.33 to 0.62* 0.47 to 0.87* –0.12 to –0.29NS
Michelson et al. 2004 [65]b ATX connuaon 0.43*** 0.29* NR
Newcorn et al. 2008 [68]b,f ATX 0.60** 0.37* NR
OROS-MPH 0.80*** 0.54* NR
JTJA (self-rated) ADHD-RS-IV Total score
Svanborg et al. 2009 [90, 91]b ATX 1.20*** 0.10NS
KINDL-R (parent-rated) SNAP-IV ADHD Physical
Well-Being
[94]
Emoonal
Well-Being
Self-Esteem Family Friends School Total score
Wehmeier et al. 2011 [94] ATX 0.72*** [38] −0.39* 0.32* 0.60*** 0.40* 0.39* 0.25NS 0.38*
Studies with funconal outcomes Symptoms Funconal impairment
BSFQ (parent/invesgator-rated)c ADHD-RS-IV Total score
Wilens et al. 2013 [100]b,h Adjuncve GXR 
a.m./p.m.
0.38/0.45***
[98]
0.38/0.39***
Wilens et al. 2010 [99]b TD-MPH 0.90*** 1.08**
SCS/SSRS (parent/teacher-rated) SNAP-IV ADHD SCS-T total score SCS-P total score SSRS-P total score
Abikoff et al. 2007 [1, 49] MPH 1.20*** 0.39* 0.13NS 0.14NS
APRS (teacher-rated) ADHD-RS-IV APRS total score
Brown et al. 2006 [17] ATX 0.62*** 0.31NS
WFIRS-P (parent-rated) ADHD-RS-IV Family Learning
and School
Life
Skills
Child’s
Self-Concept
Social
Acvies
Risky
Acvies
Total
score
Banaschewski et al. 2013 [15] LDX 1.80*** 0.73*** 1.25*** 0.24NS 0.26NS 0.64*** 0.64*** 0.92***
OROS-MPH 1.26*** 0.65*** 0.91*** 0.35* 0.36* 0.60*** 0.41* 0.77***
Hervas et al. 2014 [51] GXR 0.76*** 0.38** 0.42** 0.23NS 0.09NS 0.45** 0.21NS 0.44**
ATX 0.32* 0.16NS 0.32* 0.16NS 0.15NS 0.21NS 0.14NS 0.28*
Wilens et al. 2015 [101]b,h,i GXR 0.52*** 0.11NS 0.22NS 0.10NS –0.15NS 0.06NS –0.01-NS 0.14NS
Stein et al. 2015 [70, 86] GXR 0.77*** 0.53*** 0.46*** 0.17NS 0.05NS 0.42*** 0.34* 0.45***
Banaschewski et al. 2014 [14] LDX connuaon 1.49*** 0.86*** 0.72*** 0.23NS 0.20NS 0.20NS 0.51** 0.91***
Effect sizes have been rounded to 2 decimal places. Positive effect sizes indicate a beneficial effect of treatment compared with placebo. Italics 
indicate long-term randomized withdrawal studies
ADHD attention-deficit/hyperactivity disorder, ADHD-RS-IV ADHD Rating Scale IV (investigator-rated unless otherwise stated), APRS Aca-
demic Performance Rating Scale, ATX atomoxetine, BSFQ Before-School Functioning Questionnaire, CHIP-CE:SRF/AE Child Health and Ill-
ness Profile-Child Edition: Self-Report Form/Adolescent Edition, CHIP-CE:PRF, Child Health and Illness Profile-Child Edition: Parent Report 
Form, CHQ-PF50 Child Health Questionnaire-50-item Parent Form, GXR guanfacine extended release, HRQoL health-related quality of life, 
JTJA Jag Tycker Jag Är [I think I am], KINDL-R Revidierter Fragebogen für Kinder und Jugendliche zur Erfassung der gesundheitsbezogenen 
Lebensqualität [Revised questionnaire to assess health-related quality of life in children and adolescents], LDX lisdexamfetamine, MPH meth-
ylphenidate, NR not reported, NS not significant, OROS-MPH osmotic-release oral system methylphenidate, SCS-P/T Social Competence Scale-
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these studies (Table 5) [25, 78, 82]. Functional impairment 
was assessed in only three studies of non-stimulants, with 
significant effects of medication versus placebo in meas-
ures of global functioning, marital/family functioning and 
driving behaviour; effect sizes were about 0.3, when avail-
able [7, 79, 97].
Relationship between ADHD symptom measures 
and HRQoL/functional measures
To assess the relationship between improvements in 
ADHD symptoms and improvements in HRQoL or func-
tioning, we collated effect sizes for active treatment versus 
placebo in all studies, when reported or calculable. Data 
were available for 16 studies (19 active treatment groups) 
in children and adolescents and 14 studies in adults 
(Tables 4, 5).
Children and adolescents
Effect sizes were greater for ADHD symptom outcomes 
than for HRQoL or functional outcomes in all but two 
studies of children and adolescents; the exceptions were a 
2-week study of TD-MPH (effect sizes 0.90 for ADHD-RS-
IV and 1.08 for investigator-rated BSFQ) and an 8-week 
study of ATX (effect sizes 0.33, 0.62 and 0.60 for ADHD-
RS-IV total score and 0.47, 0.66 and 0.87 for CHQ-PF50 
Psychosocial summary score [low, medium and high dose, 
respectively]) [66, 99]. Effect sizes were 0.5 or above for 
both ADHD symptoms and at least one aspect of HRQoL 
or functioning in five out of 13 non-stimulant treatment 
groups (ATX or GXR) [42, 66, 86, 91, 94] and five out 
of six stimulant treatment groups (LDX, OROS-MPH or 
TD-MPH) [14, 15, 99]. Effect sizes of active medications 
versus placebo were 0.5 or above for ADHD symptoms but 
below 0.5 for HRQoL or functioning in five out of 13 non-
stimulant treatment groups (ATX or GXR) [17, 37, 51, 68, 
101] and one out of six stimulant treatment groups (MPH) 
[1]. Effect sizes were below 0.5 for both ADHD symptoms 
and HRQoL or functioning in the remaining three non-
stimulant treatment groups (ATX or adjunctive GXR) [51, 
65, 100].
Some studies investigated the relationship between 
ADHD symptom measures and HRQoL or functional 
measures and consistently identified significant associa-
tions. Escobar et al. [42] reported that CHIP-CE:PRF Risk 
Avoidance domain T-scores correlated moderately with 
ADHD-RS-IV total scores at baseline (Pearson’s R, −0.46; 
p < 0.05), with weak but significant correlations in the 
other four domains of the CHIP-CE:PRF and in the Risk 
Avoidance and Comfort domains of the self-rated CHIP-
CE:SRF/AE. In an 8-week GXR study, mean changes from 
baseline in WFIRS-P total score were significantly greater 
in patients who responded symptomatically (defined as a 
CGI-Improvement score of 1 or 2 with ≥30% reduction 
in ADHD-RS-IV total score) than in those who did not 
(p < 0.001) [86]. Finally, improvement in ADHD-RS-IV 
total score was significantly correlated with improvement 
in CHQ-PF-50 scores in a post hoc analysis [62] of an 
8-week study of ATX [66].
Adults
Effect sizes were greater for ADHD symptom outcomes 
than for HRQoL or functional outcomes in all but one of 
the 12 studies (seven of non-stimulants and five of stimu-
lants) that reported significant effects of medication on 
ADHD symptoms in adults (Table 5). Effect sizes were at 
Parent/Teacher, SD standard deviation, SNAP-IV Swanson, Nolan, and Pelham Rating Scale-Revised, SSRS-P Social Skills Rating System-Par-
ent, TD-MPH transdermal methylphenidate, WFIRS-P Weiss Functional Impairment Rating Scale-Parent
* p < 0.05; ** p < 0.01; *** p < 0.001 (active treatment vs placebo)
a
 Effect sizes could not be calculated for Findling et al. 2011 [45], the only study to use the Youth Quality of Life Instrument-Research Version
b
 Effect sizes of active medication versus placebo were calculated using published data (mean change, n, and SD or standard error of the mean; 
or n and F-statistic [as appropriate])
c
 CHQ-PF50 concepts, CHIP-CE:PRF subdomains and BSFQ individual items were not included
d
 Effect sizes could not be calculated for Greenhill et al. 2006 [50]
e
 ATX doses of 0.5, 1.2 or 1.8 mg/kg/day; results shown as a range across the three doses
f
 Publication does not specify which version of the CHQ was used; parent version is assumed
g
 Symptom measure was ADHD-RS-IV for all CHIP-CE:PRF studies except Dell’Agnello et al. 2009 [37], which used SNAP-IV ADHD
h
 Effect sizes were calculated from published data for the symptomatic measure (ADHD-RS-IV or SNAP-IV ADHD) but from the correspond-
ing ClinicalTrials.gov entry for the functional/HRQoL measure (CHIP-CE:PRF or BSFQ); CHIP-CE:PRF domain effect sizes could not be cal-
culated for Dell’Agnello et al. 2009 [37]
i
 Effect sizes were published for the WFIRS-P Learning and School domain and Family domain and were calculated from published data for the 
remaining domains
Table 4  continued
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Table 5  Summary of treatment effect sizes in adults
Study and instrument Treatment Effect sizes of acve treatment versus placeboa
Symptoms HRQoL
AAQoLb (self-rated) CAARS-I:SV or other Life Producvity Psychological 
Health
Life Outlook Relaonships Total
Adler et al. 2013 [3, 4]c,d,e LDX 0.94*** (ADHD-RS-IV) 0.91NT 0.63NT 0.83NT 0.37NT 0.92NT
Goto et al. 2013 [48]d ATX 0.55*** 0.29*** 0.15NS 0.21* 0.24** 0.31***
Durell et al. 2013 [40]d ATX 0.40*** 0.26** 0.23* 0.17NS 0.23* 0.27**
Adler et al. 2009a [5]f ATX 0.47*** 0.21NS 0.22* 0.17NS 0.20NS 0.24*
Adler et al. 2009b [6]d,g ATX 0.28** (AISRS) 0.27** 0.23* 0.15NS 0.19* 0.27**
Lee et al. 2014 [55] ATX 0.99** 0.47NS 0.27NS 0.45NS 0.31NS 0.53NS
Manor et al. 2012 [59] Metadoxine 0.4* (CAARS-I) NR NR NR NR 0.38*
Symptoms HRQoL and funconal impairment
AIM-Ai (self-rated) ADHD-RS-IV Performance
and Daily 
Funconing
Impact: Daily 
Interference
Impact: 
Bother/
Concern
Relaonships 
and Comm-
unicaon
Living with 
ADHD
General 
Well-Being
QoL 
quesons 
1 and 4h
Adler et al. 2013 [3, 4]c,d,e LDX 0.94*** 0.93* 0.62* 0.57* 0.31* 0.79*** 0.70*** 0.29,* 
0.44***
Symptoms Funconal impairment
GAF (invesgator-rated) CAARS-S:SV Total score
Riahi et al. 2010 [79] Reboxene 0.04NS 0.31***
Marital/partner and 
parenng measuresk
CAARS-I:SV DAS Affeconal Expression PSI Parent Domain Depression PSI Life Stress
Wietecha et al. 2012 [97] ATX 0.57***
(24 weeks)
0.24* (8 weeks) 0.35* (8 weeks)
0.33* (24 weeks)
0.16* (24 weeks)
SDS (self-rated) CAARS-O:SV or other Total score
Huss et al. 2014 [52] MPH-LA 0.55*** (ADHD-RS-IV) 0.39*
Casas et al. 2013 [25] OROS-MPHj 0.20NS 
0.49**
0.14NS
0.17NS
Rösler et al. 2013 [64, 
82]
OROS-MPH 0.39* 0.41*
Weiss et al. 2012 [96]d d-AMP 0.23NS (ADHD-RS-IV) 0.39NS
Retz et al. 2012 [78] MPH-ER 0.54*** (WRAADDS) 0.40*
Effect sizes have been rounded to 2 decimal places. Positive effect sizes indicate a beneficial effect of treatment compared with placebo
AAQoL Adult ADHD Quality of Life, ADHD attention-deficit/hyperactivity disorder, ADHD-RS-IV ADHD Rating Scale IV [investigator-rated unless oth-
erwise stated], AIM-A ADHD Impact Module-Adult, AISRS Adult ADHD Investigator Symptom Rating Scale, ATX atomoxetine, CAARS-I:SV Conners’ 
Adult ADHD Rating Scale-Investigator: Screening Version, CAARS-O:SV Conners’ Adult ADHD Rating Scale-Observer: Screening Version, CAARS-S:SV 
Conners’ Adult ADHD Rating Scale-Self-rated: Screening Version, d-AMP dextroamphetamine, DAS Dyadic Adjustment Scale, GAF Global Assessment of 
Functioning, HRQoL health-related quality of life, LDX lisdexamfetamine, MPH-ER methylphenidate extended release, MPH-LA long-acting methylpheni-
date, NR not reported, NS not significant, NT not tested, OROS-MPH osmotic-release oral system methylphenidate, PSI Parenting Stress Index, QoL quality 
of life, SD standard deviation, SDS Sheehan Disability Scale, WRAADDS Wender–Reimherr Adult Attention Deficit Disorder Scale
* p < 0.05; ** p < 0.01; *** p < 0.001 (active treatment vs placebo)
a
 Effect sizes could not be calculated for Rösler et al. 2013 [82], the only study to use the Quality of Life Enjoyment and Satisfaction Questionnaire
b
 Effect sizes could not be calculated for Adler et al. 2008 [7], which used the AAQoL, Driving Behavior Survey and Endicott Work Productivity Scale
c
 Patients with ADHD and executive function deficits. Primary efficacy outcome measure: Behaviour Rating Inventory of Executive Function-
Adult (ADHD-RS-IV secondary)
d
 Effect sizes of active medication versus placebo were calculated as the difference divided by pooled SD using published data (mean change, n, 
and SD or standard error of the mean in each group; or n in each group and F-statistic [as appropriate])
e
 Effect sizes were published for ADHD-RS-IV and calculated from the ClinicalTrials.gov study entry for the functional/HRQoL measure (AAQoL)
f
 Patients with comorbid social anxiety disorder
g
 Effect sizes were calculated using values estimated from published bar charts
h
 Effect sizes could not be calculated for AIM-A QoL questions 2 and 4; no significant differences were reported
i
 Effect sizes could not be calculated for Casas et al. 2013 [25] or for Spencer et al. 2008a and b [84, 85]
j
 OROS-MPH doses of 54 mg or 72 mg. Results for each arm are shown
k
 Only significant results are shown; 10 other outcomes were tested and were not significant (see Table 2)
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least 0.5 for both ADHD symptoms and at least one aspect 
of HRQoL or functioning in two out of these 12 studies: a 
10-week study of LDX that used the AAQoL and AIM-A 
[3, 4] and a 10-week study of ATX that used the AAQoL 
(although effects in the latter were not significant) [55]. 
Effect sizes were at least 0.5 for ADHD symptoms but 
below 0.5 for HRQoL or functioning in four out of these 
12 studies: two of long-acting MPH and two of ATX [48, 
52, 78, 97]. Effect sizes were below 0.5 for both ADHD 
symptoms and HRQoL or functioning in six out of these 
12 studies: three of ATX, two of OROS-MPH and one of 
metadoxine [25, 40, 59, 79, 82, 96].
Discussion
This systematic review aimed to evaluate HRQoL and 
functional outcomes in published randomized placebo-
controlled clinical trials of medications for ADHD. Tandem 
extraction of primary or principal symptom-based effi-
cacy outcomes alongside HRQoL and functional outcomes 
allowed the results of interest to be considered in the con-
text of the effect of study drugs on ADHD symptoms.
Baseline data from the included studies were consist-
ent with published observational studies in showing that 
children and adolescents with ADHD have substantially 
impoverished parent-rated HRQoL compared with popula-
tion norms [32, 80]. Adult HRQoL instruments used in the 
studies were nearly all ADHD specific, and baseline values 
are therefore not comparable with reference populations. 
Baseline deficits on all multi-domain HRQoL and func-
tional impairment instruments, whether generic or ADHD 
specific, or self- or proxy-rated, were more pronounced 
in domains relating to achievement/productivity, risk-tak-
ing and interpersonal relations than in other psychosocial 
domains. Little or no impairment was evident in domains 
relating to physical functioning on the generic instruments. 
Participants in the included studies were not selected based 
on HRQoL assessments, but were usually required to have 
moderate to severe ADHD symptoms (e.g. ADHD-RS-IV 
total score ≥28), indicating that the poor HRQoL observed 
at baseline is a reflection of the patients’ characteristics 
rather than the study inclusion criteria. Overall, these find-
ings support the notion that day-to-day functional impair-
ments and HRQoL deficits are typical in patients with 
ADHD.
Pharmacotherapy relieved ADHD symptoms to a signifi-
cantly greater extent than did placebo in all but two of the 
included studies, as would be expected from the large body 
of published clinical trials and recent meta-analyses [33, 
77, 88, 89]. The two studies in which no significant benefit 
over placebo was found were both small studies in adults 
(N ≤ 50), one of reboxetine and one of dextroamphetamine. 
Effect sizes of medication versus placebo for ADHD symp-
tom-based outcomes (when available) were above 0.5 
in nearly all of the included studies in children and ado-
lescents, and in most of the studies in adults. We used an 
effect size of 0.5 as an approximate but universally appli-
cable threshold for a clinically meaningful difference. This 
is supported by a study showing that nearly all estimates 
of minimum important differences for HRQoL instruments 
were close to 0.5 standard deviations and that this may cor-
respond to the limit of people’s ability to discriminate dif-
ferences over a range of criteria [71].
Functional impairment and poor HRQoL can be viewed 
as constructs that relate to, but are distinct from, ADHD 
symptoms and that reflect the impact of ADHD on patients’ 
day-to-day lives (Fig. 1). In support of this conceptual-
ization, severity of or improvement in ADHD symptoms 
correlated moderately to strongly (but not perfectly) with 
severity of or improvement in functional impairment and 
HRQoL deficits, both in the included studies for which 
this was reported [42, 62, 66, 86] and elsewhere in the lit-
erature [18, 19, 21, 32, 47, 81, 92, 95]. Furthermore, effect 
sizes (when available) of active medications versus pla-
cebo were smaller for functional or HRQoL outcomes than 
for symptom-based outcomes in nearly all of the included 
studies (Tables 4, 5). None of this evidence, however, 
reveals whether medications affect functioning and HRQoL 
directly, or only through the medium of symptom relief, or 
both.
In children and adolescents, large effect sizes (≥0.8) 
were observed for HRQoL and/or functional outcomes 
in short-term studies of long-acting stimulant medica-
tions (LDX, OROS-MPH and TD-MPH). Large effect 
sizes were not observed in any included studies of non-
stimulants (ATX and GXR) and were below 0.5 in many 
of these. Treatment effect sizes in the included studies sug-
gest that placebo-adjusted improvements in some measures 
of functioning and of HRQoL are likely to be of sufficient 
magnitude to be considered potentially clinically relevant, 
especially with stimulant treatment. Large effect sizes in 
an individual domain of an instrument may not necessar-
ily reflect large overall effects on HRQoL if some domains 
have less impact on overall HRQoL than others according 
to the instrument’s factor structure. Nevertheless, effect 
sizes on multi-domain instruments were largest in domains 
relating to achievement/school, risk-taking and interper-
sonal relations, reflecting the domains with the greatest 
deficits observed at baseline. In adults, stimulant and non-
stimulant effect sizes for functional or HRQoL outcomes 
were below 0.5 in all included studies except the single 
adult LDX study. Before drawing any conclusions about the 
effectiveness of medications or the nature of impairments 
and deficits in different age groups, however, it should be 
noted that almost all HRQoL and functional outcomes were 
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parent-rated in child/adolescent studies and self-rated in 
adult studies. If HRQoL is a subjective experience that can 
only be judged by patients themselves, then it is question-
able whether HRQoL can really be rated by parents, teach-
ers or investigators acting as proxies. Proxy-rated HRQoL 
assessments may therefore be more appropriately regarded 
as measures of functional impairment than of HRQoL.
The diversity of instruments used to assess HRQoL and 
functional impairment in the clinical trials of ADHD medi-
cations included in this review suggests a continuing lack 
of consensus in the field, and perhaps more generally, about 
which non-symptom-based outcomes should be included 
and how they should best be assessed. For example, the 
only HRQoL or functional impairment data identified in 
this systematic review for patients receiving OROS-MPH 
were from studies of LDX or ATX in which OROS-MPH 
was a reference treatment; and the only functional impair-
ment data for patients receiving ATX were from a study of 
GXR in which ATX was a reference treatment. While some 
of the differences in choice of HRQoL or functional impair-
ment outcome measure may reflect the changing demands 
of regulators, it is also the case that the design of a clini-
cal trial involves balancing inclusion of additional outcomes 
of interest with the feasibility of conducting the study and 
analysing the results. For example, the use of parent-rated 
instruments in child/adolescent studies may reflect con-
cerns that some young patients would be unable to complete 
questionnaires [31, 34], while the use of ADHD-specific 
HRQoL instruments in adults may reflect concerns that 
generic instruments would not be sensitive to the impair-
ments characteristic of ADHD in adults. The use of these 
instruments may also reflect a lack of suitable alternatives: 
this systematic review focussed only on instruments that 
have been used in published randomized placebo-controlled 
studies in patients with ADHD. These complexities reflect 
the difficulty of sampling the key domains of impairment 
in individual patients from different perspectives, without 
merely sampling symptoms. It will be interesting to see 
whether recent work to develop a standardized nomencla-
ture and toolkit to describe and code functional impairment 
in people with ADHD based on the World Health Organiza-
tion’s International Classification of Functioning, Disabil-
ity and Health will result in a more cohesive and structured 
approach to assessing HRQoL and functional impairment in 
clinical trials than at present [35, 36].
This systematic review was limited to randomized, 
double-blind, placebo-controlled studies published in peer-
reviewed journals. The limitations of this approach should 
be considered when interpreting the results. One potential 
source of bias is that secondary outcomes or entire stud-
ies that do not favour the ADHD medication being tested 
may be less likely to be published than those that indicate 
beneficial effects. To limit this bias, we excluded post hoc 
analyses because they may be more likely than pre-speci-
fied analyses to report results favouring the investigational 
product. Another potential source of bias is that the review 
did not aim to assess the safety of ADHD medications. Side 
effects, adverse events or poor tolerability may themselves 
negatively affect present or future functioning and HRQoL, 
in addition to other potentially undesirable effects. Finally, 
the review included studies with different enrolled popula-
tions: although all studies enrolled patients with diagnosed 
ADHD, recruitment criteria differed among studies. For 
example, some studies included patients with specific psy-
chiatric comorbidities or inadequate responses to previous 
ADHD medication. This could have affected the qualitative 
synthesis if study population factors are responsible for dif-
ferential effects of medication across studies. Despite these 
limitations, and the limitations of the included studies, the 
results presented here comprise the most robust available 
evidence to date that ADHD medications not only provide 
effective relief of symptoms, but may also reduce func-
tional impairments and improve HRQoL in children, ado-
lescents and adults with ADHD. Furthermore, real-world 
evidence from registry studies suggests that this may be the 
case for patients in clinical practice [16, 56, 57], as well as 
for those enrolled in clinical trials.
Whether pharmacological therapy is appropriate, and if 
so which of the treatment options and which accompanying 
behavioural or psychological intervention is most suitable 
for each patient, are decisions for healthcare professionals, 
parents and patients. The evidence presented here should 
encourage everyone involved in a patient’s treatment to aim 
for reduced functional impairment and improved HRQoL, 
as well as relief of symptoms, for all patients with ADHD.
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